Tecentriq combo meets PFS endpoint in first-line squamous NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said a combination including anti-PD-L1 mAb Tecentriq atezolizumab met the co-primary endpoint of improving progression-free survival (PFS) in the Phase III IMpower131 trial as first-line treatment of stage IV squamous non-small cell lung cancer. The company said a significant improvement on the second co-primary endpoint of overall survival (OS) was not shown at the study's interim analysis, and that the trial will continue as planned.

Both co-primary endpoints compare Tecentriq plus carboplatin and Abraxane nab-paclitaxel vs. carboplatin plus Abraxane alone. The open-label trial enrolled 1,021 patients and includes a third cohort of patients receiving Tecentriq plus carboplatin and paclitaxel. The trial’s statistical analysis plan requires that Tecentriq plus carboplatin and Abraxane significantly improve OS vs. carboplatin plus Abraxane alone before the third cohort can be compared with carboplatin plus Abraxane alone...